IFNAR2 and hepatocellular carcinoma: IFN/5‐Fu (interferon (IFN)‐a/5‐fluorouracil (5‐FU)) combination therapy is a promising therapy for advanced HCC; however, Hiroaki Nagano et al found that the response to this therapy was related to the expression of IFNAR2 ( IFN‐a type 2 receptor).